Still time to read Open Access articles of the October issue. How long is long? Drs. Chris Rowe & Don McLeod detail a study in #JCEM on long-term low dose #methimazole & lower risk of #GravesDisease relapse. https://t.co/AQy3CLJR3G #endotwitter #medtwitter #hyperthyroidism @GDATF

Still time to read Open Access articles of the October issue. Drs. Omar El-Kawkgi & Shreeyanta review research providing a risk score to predict #thyroid #hormone requirement after #lobectomy. https://t.co/PVUj5LLoDU #medtwitter #thyroidectomy #levothyroxine #endotwitter

The founders included the Export Clause because they remembered what it meant to have commerce controlled by royal prerogative—licenses sold, permissions granted or withheld at the sovereign's pleasure, arbitrary charges imposed on those who wished to trade. A 25% fee on Nvidia

Open Access. Review by Dr. Robenshtok on a @MayoClinic study showing the frequency of #thyroid #ultrasound obtained without “appropriate” indications and the associated outcomes. Read it now. https://t.co/corrGxLSzG #endotwitter #medtwitter #thyroidnodule

In this issue: Do patients w/ #hyperthyrodism need to be #euthyroid before #thyroidectomy? In Dr. Mammen’s review, understanding new meta-analysis data on the effect of perioperative management suggests similar outcomes. https://t.co/EnhWEbQkZH #endotwitter #medtwitter #thyroid

Now online: What is the role of #statins in risk of #ThyroidEyeDisease? Analysis of new paper in @thyroidjournal, Dr. Ying Gao reviews the data showing use in the first year had greatest effect. https://t.co/qz9bzcPw18 #endotwitter #medtwitter #thyroid #GravesDisease @GDATF

October issue: Dr. @SDreamMD reviews a fresh article in #JCEM comparing #parathyroidectomy vs. #parathyroid #ablation for parathyroid adenoma. How does this novel therapy stack up? https://t.co/StfQvKGsDJ #endotwitter #medtwitter #thyroid @Medscape @EndocrineToday #PTH

October issue: Dr. Ghaznavi reviews a recent #JCEM meta-analysis on recurrence risk and TSH levels with little difference between groups, confirming new @AmThyroidAssn #thyroidcancer guidelines? https://t.co/z3zM6h92XT #endotwitter #medtwitter @ThyCaInc #thyroid #DTC

October issue alert: Dr. @Simonedeleo86 reviews a study in @thyroidjournal showing more accurate risk assessment when unstimulated #thyroglobulin & its double time are considered for papillary #thyroidcancer. https://t.co/DVSFqkgWZm #endotwitter #medtwitter @ThyCaInc #thyroid

Now in the October issue – new #thyroid hormone receptor agents for #MASH are being developed. Dr. Hashimoto reviews this new paper on efficacy of #TERN501 for reducing hepatic fat content. https://t.co/WXXoc06Lmk #endotwitter #medtwitter #THRb

The October issue is out. Read/download expert reviews covering the latest in Clinical #Thyroid. https://t.co/q29gma4aYt #endotwitter #medtwitter #thyroidcancer #hypothyroidism #hyperthyroidism #Hashimotos #thyroiditis #iodine @ThyCaInc @GDATF @Medscape @EndocrineToday

It’s October & this month’s issue is here to download & read! Find expert reviews on new clinical #thyroid research. https://t.co/9CeAqDgSPK #endotwitter #medtwitter #thyroidcancer #hypothyroidism #hyperthyroidism @AmThyroidAssn @Medscape @EndocrineToday #GravesDisease

In the Sept issue: How could #Calcitonin by current assays change #surgical treatment for #MedullaryThyroidCancer? Dr. Elizabeth Cottrill breaks down the new data in @JAMAOto & what we need to know. https://t.co/bsYERiPFyh #medtwitter #endotwitter #thyroid #thyroidcancer #MTC

Read the Latest Open Access in October! What happens to #PapillaryThyroidMicrocarcinoma under #ActiveSurveillance during #pregnancy? Commentary by Drs. @DrRoweEndo & Boelaert on data pub'd in @thyroidjournal https://t.co/j0LRSSeBdr #thyroidcancer #thyroid #medtwitter #endotwitter

Read the Latest Open Access in October Report in @thyroidjournal on adjuvant treatment for locally, advanced #AnaplasticThyroidCancer from @MDAndersonNews, reviewed now by Dr. @VenessaTsang et al. https://t.co/Sd3gftrndb #thyroidcancer #thyroid #medtwitter #endotwitter #ATC

Read the Latest Open Access in October Is #RadioActiveIone needed for Low-to-Intermediate Risk #ThyroidCancer? New commentary this month on the recent IoN trial in @TheLancet. https://t.co/vTFKjKpSl4 #thyroid #medtwitter #endotwitter #DTC #RAI

What is the risk of #MTC in incidentally found germline #RET carriers? Read all about it: Article in @JAMANetworkOpen. Reviewed by Dr. Pappas now in #ClinicalThyroidology. https://t.co/S9CUssDbkO #medtwitter #endotwitter #thyroid #thyroidcancer @ThyCaInc

Read now. Excellent review by @JorisOsinga of new findings in @Eur_Thyroid_J : nationwide data analysis showing that new #hypothyroidism in #pregnancy associated w/ risk of small for gestational age. https://t.co/8abhzhBHDz #medtwitter #endotwitter #thyroid #TFT #levothyroxine

Deep learning #AI can find #pathology features identifying the genetic alteration in #papillaryThyroidCancer. Data now in @thyroidjournal & reviewed by Dr. El-Kawkgi https://t.co/HnOSqwSzhs #medtwitter #endotwitter #thyroid #thyroidcancer #PTC @EndocrineToday @Medscape @o_kawkgi

Microwave Ablation or Surgery – what to pick for Low-Risk #PTC? Review by @DrIramHussain this month in #ClinicalThyroidology looks at study showing similar outcomes between the two. https://t.co/t9Aii1PY2b #medtwitter #endotwitter #thyroid #thyroidcancer @ThyCaInc @NASITablate

New data in #JCEM suggest that the genetic prevalence of #MEN2, PHTS, and FAP is significantly higher than previously expected. Reviewed this month by Drs. @kanikshadesai & Esmaeilkhanian. https://t.co/Tg14Opx91b #medtwitter #endotwitter #thyroid #thyroidcancer @ThyCaInc